Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history:: A combined analysis of 22 studies

被引:2585
作者
Antoniou, A
Pharoah, PDP
Narod, S
Risch, HA
Eyfjord, JE
Hopper, JL
Loman, N
Olsson, H
Johannsson, O
Borg, Å
Pasini, B
Radice, P
Manoukian, S
Eccles, DM
Tang, N
Olah, E
Anton-Culver, H
Warner, E
Lubinski, J
Gronwald, J
Gorski, B
Tulinius, H
Thorlacius, S
Eerola, H
Nevanlinna, H
Syrjäkoski, K
Kallioniemi, OP
Thompson, D
Evans, C
Peto, J
Lalloo, F
Evans, DG
Easton, DF
机构
[1] Univ Cambridge, Canc Res UK Human Canc Genet Grp, Dept Oncol, Strangeways Res Labs, Cambridge CB1 8RN, England
[2] Univ Cambridge, Canc Res UK Genet Epidemiol Unit, Dept Publ Hlth, Cambridge CB1 8RN, England
[3] Univ Toronto, Ctr Res Womens Hlth, Toronto, ON, Canada
[4] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA
[5] Iceland Canc Soc, Reykjavik, Iceland
[6] Univ Iceland, Reykjavik, Iceland
[7] Univ Melbourne, Ctr Genet Epidemiol, Dept Publ Hlth, Melbourne, Vic, Australia
[8] Univ Lund Hosp, Dept Oncol, Jubileum Inst, S-22185 Lund, Sweden
[9] Natl Canc Inst, I-20133 Milan, Italy
[10] FIRC Inst Mol Oncol, Milan, Italy
[11] Princess Anne Hosp, Western Clin Genet Serv, Southampton, Hants, England
[12] Chinese Univ Hong Kong, Dept Chem Pathol, Hong Kong, Hong Kong, Peoples R China
[13] Natl Inst Oncol, Budapest, Hungary
[14] Univ Calif Irvine, Dept Med, Div Epidemiol, Irvine, CA 92717 USA
[15] Pomeranian Acad Med, Hereditary Canc Ctr, Dept Genet & Pathol, Szczecin, Poland
[16] Univ Helsinki, Cent Hosp, Dept Obstet & Gynecol, FIN-00290 Helsinki, Finland
[17] Univ Helsinki, Cent Hosp, Dept Oncol, Helsinki, Finland
[18] Tampere Univ, Canc Genet Lab, Inst Med Technol, FIN-33101 Tampere, Finland
[19] Tampere Univ Hosp, Tampere, Finland
[20] Inst Canc Res, Epidemiol Sect, Sutton, Surrey, England
[21] London Sch Hyg & Trop Med, London WC1, England
[22] St Marys Hosp, Acad Unit Med Genet, Manchester M13 0JH, Lancs, England
[23] St Marys Hosp, Reg Genet Serv, Manchester M13 0JH, Lancs, England
关键词
D O I
10.1086/375033
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Germline mutations in BRCA1 and BRCA2 confer high risks of breast and ovarian cancer, but the average magnitude of these risks is uncertain and may depend on the context. Estimates based on multiple-case families may be enriched for mutations of higher risk and/or other familial risk factors, whereas risk estimates from studies based on cases unselected for family history have been imprecise. We pooled pedigree data from 22 studies involving 8,139 index case patients unselected for family history with female (86%) or male (2%) breast cancer or epithelial ovarian cancer (12%), 500 of whom had been found to carry a germline mutation in BRCA1 or BRCA2. Breast and ovarian cancer incidence rates for mutation carriers were estimated using a modified segregation analysis, based on the occurrence of these cancers in the relatives of mutation-carrying index case patients. The average cumulative risks in BRCA1-mutation carriers by age 70 years were 65% (95% confidence interval 44%-78%) for breast cancer and 39% (18%-54%) for ovarian cancer. The corresponding estimates for BRCA2 were 45% (31%-56%) and 11% (2.4%-19%). Relative risks of breast cancer declined significantly with age for BRCA1-mutation carriers ( P trend .0012) but not for BRCA2-mutation carriers. Risks in carriers were higher when based on index breast cancer cases diagnosed at <35 years of age. We found some evidence for a reduction in risk in women from earlier birth cohorts and for variation in risk by mutation position for both genes. The pattern of cancer risks was similar to those found in multiple-case families, but their absolute magnitudes were lower, particularly for BRCA2. The variation in risk by age at diagnosis of index case is consistent with the effects of other genes modifying cancer risk in carriers.
引用
收藏
页码:1117 / 1130
页数:14
相关论文
共 49 条
  • [1] [Anonymous], CANC INCIDENCE 5 CON
  • [2] [Anonymous], 1992, Cancer incidence in five continents
  • [3] Characteristics of BRCA1 mutations in a population-based case series of breast and ovarian cancer
    Anton-Culver, H
    Cohen, PF
    Gildea, ME
    Ziogas, A
    [J]. EUROPEAN JOURNAL OF CANCER, 2000, 36 (10) : 1200 - 1208
  • [4] Antoniou AC, 2000, GENET EPIDEMIOL, V18, P173
  • [5] Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study
    Antoniou, AC
    Pharoah, PDP
    McMullan, G
    Day, NE
    Ponder, BAJ
    Easton, D
    [J]. GENETIC EPIDEMIOLOGY, 2001, 21 (01) : 1 - 18
  • [6] BASHAM VM, 2002, BREAST CANC RES, V4
  • [7] Begg CB, 2002, J NATL CANCER I, V94, P1221
  • [8] Effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history
    Claus, EB
    Schildkraut, J
    Iversen, ES
    Berry, D
    Parmigiani, G
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (23) : 1824 - 1829
  • [9] Extension of the lod score: the mod score
    Clerget-Darpoux, F
    [J]. GENETIC DISSECTION OF COMPLEX TRAITS, 2001, 42 : 115 - 124
  • [10] De Benedetti V M, 1998, Hum Mutat, V12, P215